Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP546C |
| Synonyms | |
| Therapy Description |
ASP546C is an antibody-drug conjugate (ADC) targeting CLDN18.2, which potentially induces apoptosis and cell cycle arrest and inhibits tumor growth (Cancer Res (2026) 86 (7_Supplement): 1690). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP546C | XNW27011 | CLDN18.2 Antibody 25 | ASP546C is an antibody-drug conjugate (ADC) targeting CLDN18.2, which potentially induces apoptosis and cell cycle arrest and inhibits tumor growth (Cancer Res (2026) 86 (7_Supplement): 1690). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07488676 | Phase Ib/II | ASP546C | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Recruiting | USA | 0 |